LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Merit Medical Systems Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

81.23 -1.1

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

79.48

Max

82.18

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-4.8M

28M

Pardavimai

1.7M

384M

P/E

Sektoriaus vid.

41.451

121.746

Pelno marža

7.225

Darbuotojai

7,400

EBITDA

-4.4M

80M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+30.31% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-24

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-108M

4.8B

Ankstesnė atidarymo kaina

82.33

Ankstesnė uždarymo kaina

81.23

Naujienos nuotaikos

By Acuity

50%

50%

149 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Merit Medical Systems Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-11 23:47; UTC

Karštos akcijos

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

2026-02-11 22:59; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Grab Holdings to Buy U.S.-Based Stash Financial

2026-02-11 23:54; UTC

Uždarbis

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

2026-02-11 23:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-11 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

2026-02-11 23:49; UTC

Uždarbis

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

2026-02-11 23:45; UTC

Uždarbis

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

2026-02-11 23:42; UTC

Uždarbis

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

2026-02-11 23:41; UTC

Uždarbis

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

2026-02-11 23:40; UTC

Uždarbis

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

2026-02-11 23:35; UTC

Rinkos pokalbiai

Gold Falls on Prospects of Long Fed Pause -- Market Talk

2026-02-11 23:18; UTC

Rinkos pokalbiai

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

2026-02-11 23:14; UTC

Rinkos pokalbiai

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

2026-02-11 22:59; UTC

Uždarbis

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

2026-02-11 22:59; UTC

Uždarbis

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

2026-02-11 22:59; UTC

Uždarbis

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

2026-02-11 22:58; UTC

Uždarbis

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

2026-02-11 22:57; UTC

Uždarbis

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

2026-02-11 22:54; UTC

Uždarbis

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

2026-02-11 22:53; UTC

Uždarbis

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

2026-02-11 22:47; UTC

Uždarbis

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026-02-11 22:47; UTC

Uždarbis

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026-02-11 22:23; UTC

Uždarbis

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

2026-02-11 22:22; UTC

Uždarbis

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

2026-02-11 22:22; UTC

Uždarbis

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

2026-02-11 22:19; UTC

Uždarbis

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

2026-02-11 22:18; UTC

Uždarbis

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

2026-02-11 22:18; UTC

Uždarbis

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

2026-02-11 22:18; UTC

Uždarbis

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

2026-02-11 22:16; UTC

Uždarbis

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Akcijų palyginimas

Kainos pokytis

Merit Medical Systems Inc Prognozė

Kainos tikslas

By TipRanks

30.31% į viršų

12 mėnesių prognozė

Vidutinis 105.33 USD  30.31%

Aukščiausias 122 USD

Žemiausias 90 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Merit Medical Systems Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

8

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

95.585 / 96.35Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

149 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Merit Medical Systems Inc

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
help-icon Live chat